由于GLP-1药品、多样化和AI伙伴关系,Elilly提供了强有力的长期投资机会。 Eli Lilly presents a strong long-term investment opportunity due to GLP-1 drugs, diversification, and AI partnership.
文章认为, 药品公司 Eli Lilly 提供了强大的长期投资机会, 它们的潜力与 Nvidia 在 AI 繁荣时期的潜力相比较. The article suggests Eli Lilly, a pharmaceutical company, presents a strong long-term investment opportunity, likening its potential to Nvidia's during the AI boom. 关键驱动因素包括GLP-1药物Mounjaro和抗糖尿病和肥胖的Zepbound药物,还有进一步的销售潜力。 Key drivers include the GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, with further marketing potential. 礼来公司（Eli Lilly）正在试验中通过口服减肥解决方案实现多元化，其阿尔茨海默病药物donanemab已获得FDA的批准。 Eli Lilly is diversifying with an oral weight loss solution in trials and has received FDA approval for its Alzheimer's drug, donanemab. 与OpenAI的伙伴关系旨在将AI纳入卫生保健,提高增长前景。 A partnership with OpenAI aims to integrate AI in healthcare, enhancing growth prospects.